Follow-Up and Monitoring of Adrenocortical Carcinoma

  • Britt Skogseid
  • Gerard M. Doherty


Patients with adrenocortical carcinoma (ACC) usually present with (1) symptoms caused by tumor growth and/or (2) hormone production or (3) ACC is discovered incidentally by imaging conducted for reasons other than suspicion of an adrenocortical tumor. Recurrent ACC will therefore mainly be discovered by detection of tumor growth, which can occur at the former resection site or present as distant metastases, by recurrence of symptoms of hormone access, or by biochemical evidence of rising hormone levels produced by the tumor.


Adrenocortical Carcinoma Hormone Excess Study Abnormality Urinary Steroid Profile Urine Hormone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Strosberg JR et al (2009) Management of adrenocortical carcinoma. J Natl Compr Canc Netw 7(7):752–758; quiz 759PubMedGoogle Scholar
  2. 2.
    Clark OH et al (2009) NCCN clinical practice guidelines in oncology: neuroendocrine tumors. J Natl Compr Canc Netw 7(7):712–747PubMedGoogle Scholar
  3. 3.
    Schteingart DE et al (2005) Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 12(3):667–680CrossRefPubMedGoogle Scholar
  4. 4.
    Doherty GM et al (1990) Time to recovery of the hypothalamic-pituitary-adrenal axis after curative resection of adrenal tumors in patients with Cushing’s syndrome. Surgery 108:1085–1090PubMedGoogle Scholar
  5. 5.
    Kikuchi E et al (2000) Urinary steroid profile in adrenocortical tumors. Biomed Pharmacother 54(Suppl 1):194s–197sCrossRefPubMedGoogle Scholar
  6. 6.
    Grondal S et al Steroid profile in urine: a useful tool in the diagnosis and follow up of adrenocortical carcinoma. Acta Endocrinol 122(5):656–663Google Scholar
  7. 7.
    Butt Z et al (2008) Fatigue is the most important symptom for advanced cancer patients who have had chemotherapy. J Natl Compr Canc Netw 6(5):448–455PubMedGoogle Scholar
  8. 8.
    Mock V et al (2007) Cancer-related fatigue. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 5(10):1054–1078PubMedGoogle Scholar
  9. 9.
    Hall EJ, Brenner DJ (2008) Cancer risks from diagnostic radiology. Br J Radiol 81(965):362–378CrossRefPubMedGoogle Scholar
  10. 10.
    Podoloff DA et al (2009) NCCN task force: clinical utility of PET in a variety of tumor types. J Natl Compr Canc Netw 7(Suppl 2):S1–26PubMedGoogle Scholar
  11. 11.
    Razifar P et al (2009) Masked volume wise principal component analysis of small adrenocortical tumours in dynamic [11C]-metomidate positron emission tomography. BMC Med Imaging 9:6Google Scholar
  12. 12.
    Khan TS et al (2003) 11C-metomidate PET imaging of adrenocortical cancer. Eur J Nucl Med Mol Imaging 30(3):403–410CrossRefPubMedGoogle Scholar
  13. 13.
    Miller BS et al (2010) Laparoscopic resection is inappropriate in patients with known or suspected adrenocortical carcinoma. World J Surg 34(6):1380–1385CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Department of Endocrine OncologyUppsala University Hospital, University of UppsalaUppsalaSweden
  2. 2.Department of SurgeryUniversity of Michigan Health System, The University of MichiganAnn ArborUSA

Personalised recommendations